Skip to main content
. 2023 May 8;41(25):3763–3771. doi: 10.1016/j.vaccine.2023.05.001

Fig. 2.

Fig. 2

Patient flow. The FAS and SAS included all participants who received one dose of the NVX-CoV2373 booster vaccination. The PPS included the FAS participants who had evaluable immunogenicity data and did not have significant protocol deviations that influenced the immunogenicity assessment. FAS, full analysis set; PPS, per protocol set; SAP, statistical analysis plan; SAS, safety analysis set.